Detalhe da pesquisa
1.
Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome.
Clin Lymphoma Myeloma Leuk
; 18(7): 469-474.e1, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29807802
2.
The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.
Leuk Lymphoma
; 58(8): 1893-1902, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27951729
3.
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk
; 15(4): 236-44, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25487600
4.
Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Clin Lymphoma Myeloma Leuk
; 14(1): 80-6, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24220615
5.
Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Clin Lymphoma Myeloma Leuk
; 13(2): 144-52, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23137720